STAT+: On Andrew Left and the government’s fraud case
I love the Summer Olympics. Every four years I transform into a huge fan of…
Category: drug development
venBio raises $528 million for its fifth fund
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The debate over how long to use Alzheimer’s drugs
Good morning. We have a new investigation out today about how Mount Sinai in New…
Testing GLP-1s in Alzheimer’s, and is Medicare a good negotiator?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: For-profit hospitals are getting a boost from a flood of patients
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money…
The biotech news you need from the weekend
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The worst for Dexcom may not be over
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: How Pfizer’s grand gene therapy ambitions crumbled
A decade ago, Pfizer began investing heavily in gene therapy, bringing in experimental treatments for…
STAT+: A preview of Neurocrine’s muscarinic drug readout
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
A potential rival for Wegovy and Zepbound enters the fray
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Viking accelerates development of obesity drug that could rival Wegovy, Zepbound
Viking Therapeutics plans to move its injectable obesity treatment into a Phase 3 study faster…
Merck lays off workers amid rough pharma job market
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Contradictory coverage decisions in North Carolina
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Medicare and Medicaid struggles foreshadow a rocky health insurer earnings season
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
Four health care and biotech updates to stay on top of this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Novo, Lilly shares sink due to concerns over competition
Hellloooooo. Today, we discuss the FDA’s lack of engagement with critics of MDMA for PTSD…
STAT+: Novartis not ready to admit a $3 billion mistake
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
The biotech news stories you need to know today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novartis hedges on when it might submit myelofibrosis drug for approval
LONDON — A Novartis executive on Thursday said “it’s too early to say” whether the…
It’s happy hour (for now) for Alnylam
Good morning and happy Wednesday. Today we’re talking about insulin, pharma’s ties with politicians, and…
STAT+: A second Roche obesity drug shows promise in early studies
LONDON — Roche on Wednesday reported positive early data from another of the obesity drug…
.jpg)
STAT+: Cardiovascular startup raises $260 million led by ex-Moderna execs’ new VC fund
Cardurion Pharmaceuticals, a startup that launched seven years ago with shelved cardiovascular drug candidates from…
Roche looks to have a competitive GLP-1 drug
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
What are the odds we get an heir to Paxlovid?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Element Biosciences raises another massive round
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Can you get satiety with GLP-1s without the nausea?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
uniQure shares soar on Huntington’s data
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Lilly’s obesity drug looks more potent than Novo’s in observational study
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: STAT+: Private equity and neuroscience: a novel approach to developing new treatments for neurological disorders
Neurological diseases are now the leading cause of poor health and disability worldwide. An estimated…
The biotech news you missed this week
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Senate, FTC cracking down on pharma patent shenanigans
Why do Americans pay so much more for common medications than people in other countries?…
Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Exclusive: European VC Forbion hires Dyne CEO, expands into US
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Intellia says its CRISPR-based therapy can be redosed
Want to stay on top of the science and politics driving biotech today? Sign up to get…
One firm, two conflicting takes on Alnylam’s HELIOS-B
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Could billions of dollars in AI funding lead to the same number of new drugs?
Drug discovery has quickly become the most enticing place to apply artificial intelligence. Billions of…
The findings from Alnylam’s highly anticipated readout
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about FDA approval for Sarepta drug, MSF closing access campaign and more
And so, another working week will soon draw to a close. Not a moment too…
Can JAK inhibitors bolster checkpoint inhibitors?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more
Rise and shine, everyone, another hot day is on the way. The forecast – at…
STAT+: Gilead’s twice-yearly antiviral protected women from HIV infection in large trial
Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected…
Lilly takes more actions against unapproved versions of Mounjaro
Want to stay on top of the science and politics driving biotech today? Sign up to get…
A biotech’s binary bet ends badly
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: How a tweet about a gene discovered long ago led to a $190 million startup and, maybe, hope for heart disease
A 10-person startup called Marea said Tuesday that it had raised $190 million to help…
STAT+: To feed an AI that designs new enzymes, Basecamp hunts rare proteins at the world’s end
Not many AI companies have expeditions to the rainforest on the calendar, or need scientists…
FDA offers new guidelines for Covid-19 vaccine
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about abortion pill access, employer coverage of GLP-1 drugs and more
And so, another working week will soon draw to a close. Not a moment too…
J.P. Morgan has officially jumped into early stage biotech investing
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FDA gets pointed input on ‘optimizing’ advisory committee panels
The day an FDA advisory committee met to weigh the merits of an experimental treatment…
With Avidity and Pfizer, gene therapy enters a phase
Want to stay on top of the science and politics driving biotech today? Sign up to get…